Jonathan Slonin Sells 2,836 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) insider Jonathan Slonin sold 2,836 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total value of $80,117.00. Following the completion of the sale, the insider now directly owns 95,557 shares in the company, valued at $2,699,485.25. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jonathan Slonin also recently made the following trade(s):

• On Tuesday, June 11th, Jonathan Slonin sold 5,012 shares of Pacira BioSciences stock. The stock was sold at an average price of $28.57, for a total value of $143,192.84.

Pacira BioSciences Stock Performance

Shares of NASDAQ:PCRX opened at $21.66 on Friday. The company has a market cap of $1.01 billion, a P/E ratio of 15.15 and a beta of 0.88. The company has a debt-to-equity ratio of 0.57, a quick ratio of 4.78 and a current ratio of 5.81. Pacira BioSciences, Inc. has a one year low of $20.52 and a one year high of $40.16. The business’s 50-day simple moving average is $28.53 and its 200 day simple moving average is $29.67.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Tuesday, May 7th. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.04). Pacira BioSciences had a net margin of 10.34% and a return on equity of 12.98%. The company had revenue of $167.12 million for the quarter, compared to analysts’ expectations of $165.43 million. On average, sell-side analysts forecast that Pacira BioSciences, Inc. will post 2.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pacira BioSciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Pacira BioSciences by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company’s stock worth $149,413,000 after purchasing an additional 14,960 shares during the last quarter. Frontier Capital Management Co. LLC increased its holdings in Pacira BioSciences by 15.8% during the 4th quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company’s stock worth $70,332,000 after purchasing an additional 285,045 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Pacira BioSciences by 1.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,411,767 shares of the company’s stock worth $47,633,000 after purchasing an additional 17,949 shares during the last quarter. Vestal Point Capital LP purchased a new stake in Pacira BioSciences during the 4th quarter worth approximately $40,488,000. Finally, Clearbridge Investments LLC increased its holdings in Pacira BioSciences by 2.3% during the 1st quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company’s stock worth $34,250,000 after purchasing an additional 26,463 shares during the last quarter. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PCRX. Needham & Company LLC reissued a “buy” rating and issued a $43.00 price target on shares of Pacira BioSciences in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $57.00 price target on shares of Pacira BioSciences in a research note on Tuesday. Piper Sandler restated an “overweight” rating and issued a $42.00 price objective on shares of Pacira BioSciences in a report on Wednesday. JPMorgan Chase & Co. began coverage on Pacira BioSciences in a report on Thursday, March 7th. They issued an “overweight” rating and a $45.00 price objective on the stock. Finally, Barclays downgraded Pacira BioSciences from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $38.00 to $25.00 in a report on Wednesday. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.10.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.